Bionomics Ltd. is an international biotechnology company, which discovers and develops therapeutics for cancer and diseases of the central nervous system. The company operates through three segments: Drug Discovery, Drug Development and Contract Services. The Drug Discovery segment engages in creation and ongoing testing of compounds to determine the best compound that matches the product profile. The Drug Development segment involves in ongoing testing, which includes clinical trials of the best compound with a view to commercialisation of the compound. The Contract Services segment is the provision of scientific services on a fee for service basis to both external and internal customers. Its proprietary technology platforms include MultiCore, ionX and Angene. Bionomics was founded in 1991 and is headquartered in Thebarton, Australia.